Finzati - Logo
BNR logo

Burning Rock Biotech Limited

BNR • Medical - Diagnostics & Research
Strong market move
BNR+11.22%
vs. previous close $10.78
$11.99
▲ +1.21 (+11.22%)
Current price
EarningsSep 2, 11:12 AM UTC
New financial eventQ1 2026Negative

Burning Rock Biotech Limited has reported Q1 2026 financial results

The latest report contains several weaker financial signals that deserve attention. Growth, profitability, cash generation, or financial strength may have deteriorated. The report may attract increased investor attention and price volatility.

Finzati signal
Caution warranted
Sep 2, 11:12 AM UTC
Changed
-18.89%
Revenue
Changed
-29.42%
Net income
Changed
-24.55%
Free cash flow
Changed
-9.92%
Cash
What changed
↓Revenue declined 18.9% versus the comparable prior period, indicating weaker top-line performance.
↓Net income declined 29.4%, showing weaker profitability.
↓Free cash flow declined 24.6%, indicating pressure on cash generation.
↓Cash and short-term investments declined 9.9%.
Based on newly processed financial statements and comparable prior-period data.This is informational analysis, not investment advice.
Financial data as of: Mar 31, 2026, 12:00 AM UTCLast earnings update: Sep 2, 2026, 11:12 AM UTCLast profile update: Sep 4, 2026, 12:16 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$11.99
Change11.22%
Shares Out1.05M
Market Cap$12.61M
52W Range6.79 - 41.72
Beta1.38
P/E-3.05
P/S0.31
P/B0.32
P/FCF-5.02
EV/Sales-0.53
EV/EBITDA8.95

Investment DNA

How strong this company looks for long-term investors

55
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
76/100
Growth Potential
Revenue and expansion
95/100
Price Attractiveness
Cheap or expensive today
92/100
Why this score▼
Positive revenue growth · 79.0%Manageable debt level · 0.08Healthy liquidity · 2.99Weak profitability

Analyst view

Analyst sentiment and price target

BNR
Analyst sentiment
Based on 3 analyst votes · 2026-09-05
100/100
Bullish
Bullish
3
Hold
0
Bearish
0

Company Overview

IPO: 6/12/2020
Industry: Medical - Diagnostics & Research
P/B i: 0.32
Debt / Equity i: 0.08
Operating Margin: -10.16%
Net Margin: -10.26%
ROE i: -
ROIC: -

Financial Health

Score15 / 20
Debt / Equity: 0.08
Current Ratio: 2.99
Quick Ratio: 2.76
Status: Good

Insider Transactions

Recent executive and insider activity

Han Yusheng
Transaction: 06/26/2026
BUY
Change
+24,900
Price
$8.00
Filing
07/02/2026
Type
BUY
Han Yusheng
Transaction: 06/24/2026
BUY
Change
+250,000
Price
$8.00
Filing
07/02/2026
Type
BUY
Han Yusheng
Transaction: 06/23/2026
BUY
Change
+5,990
Price
$7.50
Filing
07/02/2026
Type
BUY